Dermatomyositis associated with omalizumab therapy for severe asthma: a case report
Abstract Background Omalizumab is a humanized monoclonal antibody widely used for treatment of persistent allergic asthma and antihistamine-refractory chronic urticaria. Immediate adverse events to omalizumab are well characterized. Delayed anaphylactoid and serum sickness-like reactions have also b...
| Main Authors: | , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
BMC
2019-01-01
|
| 叢編: | Allergy, Asthma & Clinical Immunology |
| 主題: | |
| 在線閱讀: | http://link.springer.com/article/10.1186/s13223-019-0319-4 |